Biotech news

Latest breaking stories, features and analysis

Is Biogen stock a buy or sell as ALS study falls short of primary endpoints?
  • Biogen shares fell on Monday after the company announced crucial data for tofersen study.
  • The Phase 3 trial for tofersen in patients ALS did not meet primary endpoints with statistical significance.
  • The company will focus on broadening the access to experimental therapy on all eligible ALS patients.
October 18, 2021

Market analysis

Is Biogen stock a buy or sell as ALS study falls short of primary endpoints?
October 18, 2021
Top 3 undervalued US biotech stocks to buy before it is too late
October 12, 2021
Should you invest in Novavax shares after inking a covid vaccine manufacturing deal?
October 8, 2021
Should you buy SAVA stock in Q4 2021 amid positive Simufilam trial data?
September 22, 2021

More breaking stories

October 8, 2021
October 8, 2021
October 1, 2021
September 27, 2021
September 23, 2021
September 22, 2021
August 27, 2021
August 9, 2021
August 4, 2021
July 30, 2021
July 28, 2021
July 22, 2021
July 7, 2021
July 1, 2021
June 8, 2021
June 8, 2021
May 24, 2021
May 24, 2021
May 11, 2021
March 1, 2021
February 5, 2021
February 3, 2021